Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

计划入组 15 人 · 首次发布于 2024 年 8 月 5 日

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

计划入组 54 人 · 首次发布于 2021 年 8 月 31 日

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

计划入组 136 人 · 首次发布于 2026 年 5 月 6 日

1R-(E1)-(E1)

ATG-E1

B2.1-E1

AMANO ENZYME INC.

Japan

Summit Royalties Ltd

United States

Lixte Biotechnology

United States

CIT Therapeutics Secures $2.5M Partnership with IFLI to Advance Novel SUMOylation-Targeted Cancer Therapy

Azenosertib Shows Promise in Cyclin E1+ Platinum-Resistant Ovarian Cancer

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency